Leading Product Candidates
Spero Therapeutics is developing a portfolio of novel product candidates with the potential for meaningful patient impact and significant commercial applications. Our candidates are designed to treat MDR bacterial infections in both the hospital and community settings.
-
Tebipenem HBr
Oral Candidate to Treat MDR Gram-Negative Infections
Novel antibiotic currently in a Phase 3 pivotal trial with the potential to be the first oral carbapenem for use in adults in treating cUTI.
-
SPR720
Oral Candidate to Treat Non-tuberculous Mycobacterial Disease
Novel agent with the potential to be the first oral antibiotic approved for the treatment of NTM disease.
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update
- Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection
- Spero Therapeutics Announces Closing of Rights Offering
-
Investors
Learn about the investment opportunity, see our upcoming events and download our latest corporate presentation.
Investment opportunities > -
Careers
Join a passionate team that pushes the limits in finding innovative therapies to help patients.
Career opportunities > -
Partners
Our strategic partnerships foster mutually beneficial alliances that advance medicine to improve patient lives.
Partnership opportunities >
